A 2009 update on the treatment of patients with hormone receptor-positive breast cancer

Clinical Breast Cancer

Volumn 9, Issue SUPPL.1, 2009, Pages

  Cleator, Susan J ^a   Ahamed, Eliyaz ^a   Coombes, R Charles ^a,b   Palmieri, Carlo ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Estradiol; Estrogen receptor; Neoadjuvant therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GONADORELIN AGONIST; LAPATINIB; LETROZOLE; LONAFARNIB; P 02411; PLACEBO; SIGNAL TRANSDUCTION INHIBITOR; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DNA POLYMORPHISM; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECT; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 70249088410     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.s.001     Document Type: Article

References (94)

1. Anderson W F, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36.
2. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
3. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002;94:1433-4.
4. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
5. Osborne CK, Schiff R, Fuqua SA, et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7(suppl) :4338s-42s.
6. Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002;9:1-13.
7. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005;19:833-42.
8. Nicholson RI, McClelland RA, Robertson J F, et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87.
9. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
10. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
11. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16.
12. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
13. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
14. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92.
15. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
16. Arimidex, Tamoxifen, Alone or in Combination (ATAC) trialists' group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
17. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-16.
18. Kapp AV, Jeffrey SS, Langerød A, et al. Discovery and validation of breast cancer subtypes [published correction appears in BMC Genomics 2007;8:101].
19. BMC Genomics 2006;7:231.
20. Breast International Group (BIG) 1-98 collaborative group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published correction appears in N Engl J Med 2006;354:2200].
21. N Engl J Med 2005;353:2747-57.
22. Brinton LA, Sherman ME, Carreon JD, et al. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008;100:1643-8.
23. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
24. Albain K, Barlow W, O'Malley F, et al. Concurrent ICAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 (SWOG-8814). Paper presented at: The 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX. Abstract 37.
25. Peto R, Davies C. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter) : international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women-preliminary results. Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-17, 2007; San Antonio, TX. Abstract 48.
26. Gray RG, Rea DW, Handley K, et al. aTTom (Adjuvant Tamoxifen-To Offer More?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6, 934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-preliminary results. J Clin Oncol 2008;26(suppl) :10s (abstract 513).
27. Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
28. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-27.
29. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 2002;20:4621-7.
30. Roché H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006;17:1221-7.
31. Price KN, Goldhirsch A. Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res 2005;7:252-4.
32. Forward D P, Cheung KL, Jackson L, et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90:590-4.
33. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
34. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
35. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
36. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-65.
37. Coombes RC, Kilburn LS, Snowdon C F, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study) : a randomised controlled trial [published correction appears in Lancet 2007;369:906].
38. Lancet 2007;369:559-70.
39. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
40. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive earlystage breast cancer: a meta-analysis [published correction appears in Lancet Oncol 2007;8:6].
41. Lancet Oncol 2006;7:991-6.
42. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2008;69(suppl) :66s (abstract 13).
43. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Breast Cancer Res Treat 2008;69(suppl) :67s (abstract 15).
44. Ingle JN, Dowsett M, Cuzick J, et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Breast Cancer Res Treat 2008;69(suppl) :66s (abstract 12).
45. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a). J Clin Oncol 2005;23(suppl) :10s (abstract 527).
46. Mamounas E P, Jeong J-H, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-71.
47. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
48. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
49. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-17, 2007; San Antonio, TX. Abstract 10.
50. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001;11:489-99.
51. Sachse C, Brockmöller J, Hildebrand M, et al. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998;8:181-5.
52. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
53. Stearns V, Rae JM. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 2008;10:e34.
54. Goetz M, Ames M, Gnant M, et al. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. Cancer Res 2009;69(suppl) :76s (abstract 57).
55. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
56. Haiman CA, Dossus L, Setiawan V W, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007;67:1893-7.
57. Sowers MR, Wilson AL, Kardia SR, et al. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/ multiethnic, multisite study of women at midlife. Am J Med 2006;119(suppl 1):S23-30.
58. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-6.
59. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
60. van der Hage JA, van de Velde CJ, Julien J-P, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
61. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;96-102.
62. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8.
63. Guarneri V, Broglio K, Kau S-W, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
64. Semiglazov V F, Semiglazov V V, Dashian GA, et al. Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer [in Russian]. Vopr Onkol 2007;53:400-8.
65. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004;91:699-704.
66. Hellman S, Harris J. Natural history of breast cancer. In: Harris JR, Hellman S, Henderson IC, et al, eds. Breast Diseases. 2nd Ed. Philadelphia, PA: JB Lippincott Company; 1991:165-81.
67. Breast cancer. National Comprehensive Cancer Network Practice Guidelines in Oncology-v. 1.2009. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed: May 17, 2009.
68. Broglio K, Moulder SL, Hsu L, et al. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. J Clin Oncol 2008;26(suppl) :41s (abstract 1001).
69. MacFarlane R, Speers C, Masoudi H, et al. Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 2008;26(suppl) :41s (abstract 1000).
70. Bonneterre J, Buzdar A, Nabholtz J-MA, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
71. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90.
72. Thürlimann B, Robertson J F, Nabholtz JM, et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as firstline treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39:2310-7.
73. Gennatas C, Michalaki V, Carvounis E, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole: a phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006;92:13-7.
74. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70.
75. Ellis MJ, Llombart A, Rolski J, et al. A comparison of high-dose (HD, 500 mg) fulvestrant vs anastrozole (1 mg) as first-line treatments for advanced breast cancer: results from FIRST. Breast Cancer Res Treat 2008;69(suppl) :397s (abstract 6126).
76. Ellis MJ, Dehdahti F, Kommareddy A, et al. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. Breast Cancer Res Treat 2008;69(suppl) :68s (abstract 16).
77. Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80(suppl 1):S19-26.
78. Stanway SJ, Purohit A, Woo LW, et al. Phase I study of STX 64 (667 coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92.
79. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
80. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
81. Osborne K, Neven P, Dirix L, et al. Randomized phase II study of gefitinib (Iressa) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):S107 (abstract 2067).
82. Cristofanilli M, Valero V, Mangalik A, et al. A phase II multicenter, double-blind, randomized trial to compare anastrozole plus [gefitinib] with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 2008;26(suppl) :44s (abstract 1012).
83. Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial [published correction appears in Lancet Oncol 2005;6:357].
84. Lancet Oncol 2005;6:383-91.
85. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22.
86. Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progressionfree survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100(suppl 1):S5 (abstract 3).
87. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC) : first results from the EGF30008 trial. Cancer Res 2009;69(suppl) :74s (abstract 46).
88. Shaw RJ, Cantley LC. Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
89. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004;10:8059-67.
90. Rudolf J, Boulay A. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitor letrozole in breast carcinomas. Proc Amer Assoc Cancer Res 2004;45: (abstract 5619).
91. Baselga J, van Dam PA, Greil R, et al. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol 2008;26(suppl) :13s (abstract 530).
92. Chow LW, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006;100(suppl 1):S286 (abstract 6091).
93. Johnston SR, Semiglazov V F, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327-35.
94. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.